11 Dec

How Would Kyndrisa Treat Duchenne Muscular Dystrophy?

WRITTEN BY Margaret Patrick

Treatment for Duchenne Muscular Dystrophy

BioMarin Pharmaceutical’s (BMRN) Kyndrisa (drisapersen) targets Duchenne Muscular Dystrophy (or DMD) Amenable to Exon 51 Skipping. According to the drisapersen advisory committee briefing document submitted by BioMarin Pharmacetical to the FDA (U.S. Food and Drug Administration), “Duchenne muscular dystrophy is caused by genetic mutation resulting in the relative absence of functional dystrophin, a rod-shaped protein necessary for the integrity and function of muscle fibers.”

Dystrophin is required to protect the muscles from the stress of contractions. BioMarin Pharmaceutical explains the outcome of the absence of dystrophin as “lack of the muscle isoform of dystrophin results in degeneration of muscle fibers, attracting inflammatory cells, and ultimately replacement of muscle by fibrosis and adipose tissue.” This eventually results in progressive muscle weakening, which affects the patient’s mobility.

How Would Kyndrisa Treat Duchenne Muscular Dystrophy?

The above diagram shows the breakdown of DMD patients targeted by BioMarin Pharmaceutical’s existing as well as pipeline drugs, segmented by exon.

According to Muscular Dystrophy UK, “Genes are divided into sections called exons and introns. Exons are the sections of DNA that code for the protein and they are interspersed with introns which are also sometimes called ‘junk DNA’. The introns are cut out and discarded in the process of protein production, to leave just the exons. The dystrophin gene is our largest gene- it has 79 exons which are joined together like the pieces of a puzzle.”

Muscular Dystrophy UK further explains the role of exon in DMD: “In Duchenne muscular dystrophy an exon, or exons are deleted which interfere with the rest of the gene being pieced together.”

BioMarin Pharmaceutical plans to treat approximately 45,000 DMD patients with its exon-skipping products. According to Muscular Dystrophy UK, “As the name suggests, the principle of exon skipping is to encourage the cellular machinery to ‘skip over’ an exon. Small pieces of DNA called antisense oligonucleotides (AOs) or ‘molecular patches’ are used to mask the exon that you want to skip, so that it is ignored during protein production.”

BioMarin Pharmaceutical is involved in developing several drugs that address various exon deletions resulting in DMD.

How Would Kyndrisa Treat Duchenne Muscular Dystrophy?

Kyndrisa

BioMarin’s drisapersen briefing document describes Kyndrisa (drisapersen) as follows: “Drisapersen is a chemically modified RNA oligonucleotide with a sequence optimized to specifically bind and skip exon 51 in the dystrophin pre-mRNA, allowing synthesis of an internally shortened but largely functional dystrophin protein.”

Kyndrisa is targeted to treat DMD patients who suffer from the deletion of exon 50. By the method of exon-skipping, the drug masks exon 51, resulting in production of the dystrophin protein.

The FDA advisory committee has given an unfavorable opinion to Kyndrisa. But most analysts estimate the probability of FDA approval for the drug to be about 50%. If approved, the drug will substantially add to BioMarin Pharmaceutical’s revenues, making it a strong competitor to peer biotechnology companies such as Amgen (AMGN), Celgene (CELG), and Gilead Sciences (GILD).

Investors can participate in the upside potential of Kyndrisa and still avoid excessive company-specific risks by investing in the Vanguard Extended Market ETF (VXF). BioMarin Pharmaceutical accounts for about 0.39% of VXF’s total holdings.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.38.64